Mabwell, an innovation-driven biopharmaceutical company with fully integrated capabilities spanning research and development, manufacturing, and commercialisation, announced that China’s National Medical Products Administration (NMPA) has approved the initiation of clinical trials for its independently developed B7-H3–targeting antibody–drug conjugate (ADC), 7MW3711.

The approved study will evaluate 7MW3711 in combination with a PD-1/VEGF bispecific antibody, JS207, developed by Junshi Biosciences, with or without platinum-based chemotherapy, including cisplatin or carboplatin, in patients with advanced solid tumours.

7MW3711 is a next-generation B7-H3–targeting ADC developed using Mabwell’s proprietary IDDC platform. The candidate has already received regulatory clearance to conduct clinical trials for advanced solid tumours in both China and the United States, underscoring the company’s progress in advancing globally aligned ADC development and manufacturing programmes. In addition, the therapy has been granted Orphan Drug Designation by the US Food and Drug Administration for the treatment of small cell lung cancer.

According to publicly disclosed clinical data, 7MW3711 has demonstrated a manageable safety profile along with encouraging anti-tumour activity in patients with advanced malignancies, including lung cancer and oesophageal cancer. These results support further clinical evaluation and scale-up of development activities.

The latest NMPA approval reflects Mabwell’s growing focus on strengthening its ADC manufacturing pipeline and expanding combination strategies that leverage its in-house technology platforms. By integrating R&D innovation with end-to-end manufacturing capabilities, the company aims to accelerate the translation of novel biologics from laboratory to clinic.

Mabwell operates across the entire biopharmaceutical value chain, encompassing discovery, process development, manufacturing, and commercialisation. The company remains committed to advancing high-quality, accessible innovative medicines while building robust manufacturing capabilities to support global clinical and commercial supply.